PLUS1
497.00
3.68 (0.75%)
3.68 (0.75%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Pro
Monthly Subscription
for only
|
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc | REGN | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.0% | 493.32 | 486.33 | 503.2623 | 495.56 | 493.32 | 00:00:03 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 480.00 | 499.90 | 19.90 | 3.98% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 19,034 | 1,169,783 | $ 494.82 | $ 578,837,265 | 1,810,523 | 271.37 - 518.00 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:27:07 | 25 | $ 497.00 | USD |
Regeneron Pharmaceuticals Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 54.27B | 110.02M | $ 2.44B | 18.45 | 27.00 | 108.21M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Regeneron Pharmaceuticals News
| Date | Time | Source | News Article |
|---|---|---|---|
| 4/03/2020 | 16:51 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 4/03/2020 | 16:50 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 4/03/2020 | 16:09 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 4/03/2020 | 16:06 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 4/03/2020 | 09:29 | Dow Jones News | Sanofi CEO: 'The One-Meeting Trip Will Disappear' |
| 4/03/2020 | 07:29 | Dow Jones News | Recession Blue-Chips' Led the Way in Another Turbulent Week.. |
| 4/03/2020 | 00:59 | PR Newswire (US) | Dupixent® (dupilumab) Phase 3 Data at Revolutionizing Atopic.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical REGN Price Data
| Period †| Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 463.09 | 503.2623 | 449.52 | 490.21 | 1,422,833 | 30.23 | 6.53% |
| 1 Month | 466.94 | 518.00 | 418.01 | 467.65 | 1,682,146 | 26.38 | 5.65% |
| 3 Months | 380.01 | 518.00 | 328.125 | 435.90 | 1,334,059 | 113.31 | 29.82% |
| 6 Months | 281.66 | 518.00 | 278.00 | 398.73 | 1,008,836 | 211.66 | 75.15% |
| 1 Year | 408.00 | 518.00 | 271.37 | 362.15 | 889,880 | 85.32 | 20.91% |
| 3 Years | 383.94 | 543.5518 | 271.37 | 380.72 | 829,371 | 109.38 | 28.49% |
| 5 Years | 434.26 | 605.9299 | 271.37 | 400.99 | 814,709 | 59.06 | 13.6% |
Regeneron Pharmaceuticals Description
| Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has six marketed products: Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Zaltrap in colorectal cancer; Dupixent in atopic dermatitis, asthma, and nasal polyposis; Libtayo in cutaneous squamous cell carcinoma; Arcalyst in CAPS; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal antibodies with Sanofi in immunology and cancer. |
